Skip to main content
Evidence Snapshot

Proto-oncogene tyrosine-protein kinase ROS

CHEMBL5568 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5568
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Proto-oncogene tyrosine-protein kinase ROS as ChEMBL target CHEMBL5568, mapped to UniProt P08922. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Proto-oncogene tyrosine-protein kinase ROS
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5568
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P08922
Proto-oncogene tyrosine-protein kinase ROS
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Proto-oncogene tyrosine-protein kinase ROS matters

As of 2026-09-14

Proto-oncogene tyrosine-protein kinase ROS is reviewed as Proto-oncogene tyrosine-protein kinase ROS (UniProt P08922); Proto-oncogene tyrosine-protein kinase ROS shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 21 approved drugs, 1772 compounds, and 412 assays, with lead potency reaching pChEMBL 10.7.

Protein context
Proto-oncogene tyrosine-protein kinase ROS

Proto-oncogene tyrosine-protein kinase ROS Sequence length is 2347 aa.

Review this target as Proto-oncogene tyrosine-protein kinase ROS, mapped to UniProt P08922. Sequence length is 2347 aa.

Protein source · UniProt accession via ChEMBL component mapping
UniProt P08922 Protein
Disease context
neoplasm

Proto-oncogene tyrosine-protein kinase ROS shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CRIZOTINIB, ENTRECTINIB, REPOTRECTINIB.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include CRIZOTINIB, ENTRECTINIB, REPOTRECTINIB, TALETRECTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 21 approved drugs, 1772 compounds, and 412 assays for this target. The dominant activity type is KI. CHEMBL3128069 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL3128069 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
21 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Proto-oncogene tyrosine-protein kinase ROS matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P08922, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1772
Total Compounds
412
Total Assays
21
Approved Drugs
IC50: 422.0, KI: 537.0, EC50: 1.0, KD: 137.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3128069
 10.7 Ki —
No preferred name
CHEMBL388978
 10.2 IC50 —
No preferred name
CHEMBL4298138
 10.2 IC50 Approved
No preferred name
CHEMBL3286830
 10.0 Ki Approved
No preferred name
CHEMBL5712062
 10.0 Ki —

Approved Drugs

Structure Compound First Approval
REPOTRECTINIB
CHEMBL4298138
 2023
ENTRECTINIB
CHEMBL1983268
 2019
FEDRATINIB
CHEMBL1287853
 2019
LORLATINIB
CHEMBL3286830
 2018
GILTERITINIB
CHEMBL3301622
 2018
BRIGATINIB
CHEMBL3545311
 2017
MIDOSTAURIN
CHEMBL608533
 2017
CERITINIB
CHEMBL2403108
 2014
CRIZOTINIB
CHEMBL601719
 2011
PAZOPANIB
CHEMBL477772
 2009
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5568